GLP-1 Drugs After Failed Bariatric Surgery: Evidence for Treating Insufficient Weight Loss
Review examines the growing evidence for GLP-1 receptor agonists as adjunctive therapy for patients with insufficient weight loss or weight regain after bariatric surgery.
Quick Facts
What This Study Found
GLP-1 receptor agonists consistently produce meaningful additional weight loss in bariatric surgery patients with insufficient weight loss or weight regain.
Key Numbers
100 patients were included, with 96 having undergone sleeve gastrectomy. Specific weight loss data from GLP-1 treatment was analyzed but not detailed in available abstract.
How They Did This
Review of clinical studies examining GLP-1 RA use in post-bariatric surgery patients with insufficient weight loss or weight regain.
Why This Research Matters
Bariatric surgery failure or weight regain affects hundreds of thousands of patients with limited treatment options. GLP-1 drugs offer a non-surgical rescue strategy.
The Bigger Picture
The combination of surgical and pharmacological approaches to obesity represents the future of metabolic medicine. Rather than viewing bariatric surgery as the last resort, clinicians increasingly see it as one tool that can be enhanced with peptide-based medications.
What This Study Doesn't Tell Us
Most studies are observational or small trials. Optimal timing, dose, and duration of GLP-1 therapy after surgery are not established. Insurance coverage for GLP-1 drugs post-surgery varies.
Questions This Raises
- ?Should GLP-1 drugs be started routinely after bariatric surgery to prevent weight regain?
- ?Which GLP-1 drug works best after each type of bariatric procedure?
- ?How long should post-surgical GLP-1 therapy continue?
Trust & Context
- Key Stat:
- Post-surgical rescue GLP-1 drugs consistently produce additional weight loss in patients who did not lose enough weight from bariatric surgery alone
- Evidence Grade:
- Moderate evidence: review of available studies showing consistent benefit, though most are observational or small-scale.
- Study Age:
- Published in 2025. Addresses a growing clinical need as both bariatric surgery and GLP-1 prescribing increase.
- Original Title:
- Interest in Treatment with GLP-1 Receptor Agonists for the Management of Insufficient Weight Loss or Weight Regain After Bariatric Surgery.
- Published In:
- Obesity surgery, 35(10), 4286-4291 (2025)
- Authors:
- Abdallah, Hussein, Klink, Wissam Hadi, Derienne, Joseph, Voican, Cosmin, Perlemuter, Gabriel, Courie, Rodi, Dagher, Ibrahim, Tranchart, Hadrien
- Database ID:
- RPEP-09729
Evidence Hierarchy
Frequently Asked Questions
Can GLP-1 drugs help if bariatric surgery didn't work well enough?
Yes. This review shows GLP-1 drugs consistently help post-surgical patients lose additional weight. They work through different mechanisms than surgery, so the combination can be more effective than either approach alone.
Is it safe to take GLP-1 drugs after bariatric surgery?
Available data suggests GLP-1 drugs are generally safe after bariatric surgery, though patients may be more sensitive to GI side effects. Close monitoring by a specialist is recommended, especially after procedures that alter gut anatomy.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09729APA
Abdallah, Hussein; Klink, Wissam Hadi; Derienne, Joseph; Voican, Cosmin; Perlemuter, Gabriel; Courie, Rodi; Dagher, Ibrahim; Tranchart, Hadrien. (2025). Interest in Treatment with GLP-1 Receptor Agonists for the Management of Insufficient Weight Loss or Weight Regain After Bariatric Surgery.. Obesity surgery, 35(10), 4286-4291. https://doi.org/10.1007/s11695-025-08210-y
MLA
Abdallah, Hussein, et al. "Interest in Treatment with GLP-1 Receptor Agonists for the Management of Insufficient Weight Loss or Weight Regain After Bariatric Surgery.." Obesity surgery, 2025. https://doi.org/10.1007/s11695-025-08210-y
RethinkPeptides
RethinkPeptides Research Database. "Interest in Treatment with GLP-1 Receptor Agonists for the M..." RPEP-09729. Retrieved from https://rethinkpeptides.com/research/abdallah-2025-interest-in-treatment-with
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.